Relmada Therapeutics (RLMD) stock

Bladder cancer treatments , market cap $367M

Bladder cancer treatments

Market cap $367M

$3.84

+7.26%

As of Monday's close · Live for Pro members at the open

Quality Score

Below Average

In its industry

#116of 291

Biotech

Checks firing

5of 14

Trending down

From 52-week high

-52.0%

Below the 200-day

RLMD's Quality Score rose 2 points on Mon, Nov 2, to 1.

Follow RLMD's trial news. Pro members can get an alert when Relmada Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when RLMD files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEnd of 2026“NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway.”Filing with regulators · SEC filing · Aug 6

Key facts on RLMD

Key facts on RLMD
Holding it back	3.4 times as many shares as a year ago
Latest filing	10-Q, Aug 6 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

1 more reason behind RLMD's 1, free with an account →4 more reasons behind RLMD's 1, for Pro members.

RLMD in the news

TodayNo story names it yet.

RLMD catalysts

Coming up

After its last 4 reports it closed -2.3% on average, higher 2 of 4 times.

1 past catalyst since 2026, with sizes and sources, for Pro members.Get in free →

What's next for RLMD, and how long its cash lasts

Next step the company has named

End of 2026“NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway.”Filing with regulators · SEC filing · Aug 6

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

Lead program: NDV-01 · Bladder (Urothelial, Transitional Cell) Cancer · Phase 3
Its trial: RESCUEPhase 3 · Not yet recruiting · 393 people · main data estimated Dec 2029 · NCT07464145

1 more trial, 35 filings, for Pro members.

Cash runway

The company says its cash lasts through 2029 (8-K, Aug 6).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed May 13, 2026)
At-the-market share sales program (S-3ASR, filed May 13, 2026)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

CFO Maged Shenouda bought 200,000 shares on Sep 10. 1 more insider trade this year.

From Form 4: open-market buys and sales only.

Get an alert when Sergio Traversa buys or sells

For Pro members: every trade, and Sergio Traversa’s 11 filings and quotes.

Get an alert when RLMD files news on its trialsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 20 daysFDA decisionIn 20 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $385MDeramiocelFDA decision due (PDUFA)
In 20 daysFDA decisionIn 20 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $1.0BMolgramostimFDA decision due (PDUFA)
In 50 daysFDA decisionIn 50 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.9BLorundrostatFDA decision due (PDUFA)

11 more FDA dates and 102 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 143 dates, ranked →

Why RLMD scores 1

Below Averagefor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means

+5Chart checks 5 of 14 firing right now, one point each
−2Dilution 3.4 times as many shares outstanding as a year agoNew shares over the year: -1 at 10% more, -2 at 25% more.

Long-term trend subtracts
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
Insider trades adds

No effect today: Run-up, Size, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on RLMD and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:06 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when RLMD's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on RLMD and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

RLMD has 5 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on RLMD, and all 14 on every stock.Get in free →

RLMD RSI today: 60.7, above its 50-day, below its 200-day

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1460.7
Above 50, below 70.
MACD (12, 26, 9)Above signal
Crossed above its signal line 9 sessions ago.
50-day average$3.83
The price is 0.3% above it.
200-day average$5.36
The price is 28.4% below it.
50/200 crossDeath cross
The 50-day crossed below the 200-day on Sep 1.
ADX 1433.7
25 or more, with +DI above -DI.
Support$3.70
Swing low from Dec 3, 2025, 3.6% below the price.
Resistance$4.35
Swing high from Feb 9, 13.2% above the price.
52-week high$8.00
From May 6, 108.3% above the price.
52-week low$2.15
From Nov 3, 2025, 44.0% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Above
The bands run from $2.99 to $3.66.
Volume1.4x
Against its 20-day average, for the time of day.

The deep dive on RLMD

What it does and how it makes money2 findingsFor Pro members2 findings on what RLMD does and how it makes money, for Pro members
Where it stands2 findingsFor Pro members2 findings on where RLMD stands: its cash, debt, and share count, for Pro members
What changed in its filings1 finding"These conditions raise substantial doubt about our ability to continue as a going concern." (10-K for fiscal 2013)SEC filing · Dec 16, 2013
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades RLMD, for Pro members

6 more findings on RLMD, each with its source, for Pro membersGet in free →

How RLMD ranks in Biotech

RLMD is #116 of 291 by Quality Score.

How RLMD ranks in Biotech
1	KNSAKiniksa Pharmaceuticals International	6/14	21
2	TGTXTG Therapeutics	8/14	19
3	AMGNAmgen	5/14	19
	RIGLRigel Pharmaceuticals		Open for its score
	RLAYRelay Therapeutics		Open for its score
	RPRXRoyalty Pharma		Open for its score
	RVMDRevolution Medicines		Open for its score
116	RLMDRelmada Therapeutics	5/14	1

When does RLMD report earnings, and what happens after?

Expected to report Thu Nov 12, after the close (in 10 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

-3.5%+0.5%-8.0%

Mar 20May 12Aug 6

Reported	When	Gap	Reaction	5 sessions
Aug 6, 2026After close	After close	+1.4%	-8.0%	-11.6%
May 12, 2026After close	After close	0.0%	+0.5%	-5.6%
Mar 20, 2026After close	After close	0.0%	-3.5%	+5.9%

RLMD closed higher after 2 of its last 4 reports.

All 4 reports, and RLMD's Quality Score going into each

Everyone reporting earnings next week

RLMD share count over time

Shares: 3.4 times the count a year ago (to Jun 30).

Shares of RLMD outstanding, as filed
Shares outstanding	As of
106.7M	Aug 4, 2026
104.9M	May 7, 2026
104.9M	Mar 16, 2026
73.3M	Nov 10, 2025

Offerings, shelves, and splits of RLMD, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	May 13, 2026
Registered shares for a later sale (S-3)	Apr 3, 2026
Set up an at-the-market program for up to $100M of shares, about 27% of its market value	Jan 30, 2026
Raised $2.6M in a sale of shares	Nov 5, 2025

2 more offerings on file, for Pro members.

Insiders trading RLMD

RLMD insider trades

2 insiders bought $1.7M across 4 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyMaged Shenouda$505KChief Financial Officerat $4.20 on Sep 9, filed Sep 11

BuyMaged ShenoudaChief Financial Officer$505Kat $4.20 on Sep 9, filed Sep 11

All 4 insider filings on RLMD from the last six months, for Pro members.Get in free →

All RLMD insider trades

RLMD's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Sergio TraversaChief Executive Officer · 4 trades
Maged ShenoudaChief Financial Officer · 4 trades
Chuck EnceCAO and COO · 1 trade
Paul Edward KellyChief Operating Officer · 1 trade

See insider trades by person

Which ETFs hold RLMD?

In ETFs: RLMD is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Relmada Therapeutics

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

17 employeesCoral Gables, FLrelmada.com

RLMD's score card

Relmada Therapeutics (RLMD): Quality Score 1, Below Average, #116 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn RLMD's score around: 8 things
7 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaySep 11Maged Shenouda bought RLMD$505K at $4.20, filed Sep 11

Alerts are optional.

See RLMD's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 2, 2026: RLMD's Quality Score is 1 (Below Average), #116 of 291 in Biotech. Insiders bought $1.7M in the last 6 months (Form 4).

Is RLMD a good stock to buy? What its Quality Score says

RLMD scores 1 today, which Breakaway calls Below Average. It is #116 of 291 in Biotech by Quality Score, with 5 of 14 chart checks firing. Shares: 3.4 times the count a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is RLMD's Quality Score?

RLMD scores 1 today, which Breakaway calls Below Average (0 to 5). That is #116 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind RLMD's 1.

Are insiders buying RLMD?

2 insiders bought $1.7M across 4 filings in the last 6 months. No open-⁠market sales on record. The newest is Maged Shenouda, Chief Financial Officer, who bought $505K on Sep 9. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.